- Home
- COYA vs UNCY Comparison
COYA vs UNCY Comparison
Compare COYA & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | UNCY |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 141.8M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | COYA | UNCY |
|---|---|---|
| Price | $4.59 | $7.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $15.80 | ★ $44.50 |
| AVG Volume (30 Days) | 326.8K | ★ 539.4K |
| Earning Date | 03-17-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,987,706.00 | N/A |
| Revenue This Year | $70.00 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.94 | $3.71 |
| 52 Week High | $8.29 | $11.00 |
Technical Indicators
Market Signals| Indicator | COYA | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 61.19 |
| Support Level | $4.51 | $6.60 |
| Resistance Level | $4.82 | $7.29 |
| Average True Range (ATR) | 0.36 | 0.48 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 44.17 | 82.93 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.